公开(公告)号：US20220211755A1

公开(公告)日：2022-07-07

申请号：US17696321

申请日：2022-03-16

申请人： The Trustees of Columbia University in the City of New York

发明人： Donald O. Freytes ,  Gordana Vunjak-Novakovic ,  John O'Neill

IPC分类号： A61K35/12 ,  C12N5/00 ,  C12N5/071 ,  A61K35/22

摘要： Region-specific extracellular matrix (ECM) biomaterials are provided. Such materials include acellular scaffolds, sponges, solutions, and hydrogels suitable for stem cell culture.

公开(公告)号：US20220211754A1

公开(公告)日：2022-07-07

申请号：US17607850

申请日：2020-04-29

申请人： PAEAN BIOTECHNOLOGY INC.

发明人： Kyuboem HAN ,  Chun-Hyung KIM ,  Shin-Hye YU ,  Seo-Eun LEE ,  Sang-Min LIM ,  Hahnsun JUNG ,  Kwangmin NA ,  Yoon Mi HAN ,  Jun Young SON ,  Eun Young LEE ,  Jeong Yeon KIM ,  Yeong Wook SONG ,  Jin Chul PAENG ,  Yun Sang LEE ,  Do Won HWANG

IPC分类号： A61K35/12 ,  A61K35/30 ,  A61K35/17 ,  A61K35/33 ,  A61K35/19 ,  A61K35/35 ,  A61K35/28 ,  A61K35/34 ,  A61K35/50 ,  A61K35/52 ,  A61K35/54 ,  A61K35/545

摘要： The present invention relates to a pharmaceutical composition for preventing or treating myositis. More particularly, the present invention relates to a pharmaceutical composition for preventing or treating myositis, comprising mitochondria as an active ingredient. When the pharmaceutical composition of the present invention comprising exogenous mitochondria as an active ingredient is administered to a subject suffering from myositis, inflammatory cells infiltrated into the muscle cells of the subject can be reduced. In addition, the pharmaceutical composition of the present invention effectively inhibits the expression of IL-1β, TNF-α, and IL-6, inflammatory cytokines. Therefore, the pharmaceutical composition according to the present invention can be usefully used for preventing or treating myositis.

公开(公告)号：US11377636B2

公开(公告)日：2022-07-05

申请号：US16563089

申请日：2019-09-06

申请人： Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft ,  University of Bath

发明人： Jichang Wang ,  Zsuzsanna Izsvák ,  Laurence Daniel Hurst

IPC分类号： C12Q1/68 ,  C12N15/63 ,  A61K35/12 ,  C07H21/04 ,  C12N5/0735 ,  C12N5/074

摘要： An in vitro method for identifying, isolating and/or enriching primate naive pluripotent stem cells, the method including analyzing transcription of a type 7 long terminal repeat (LTR7) nucleic acid sequence of a type H human endogenous retrovirus (HERVH) (LTR7/HERVH-associated transcription), and identifying, isolating and/or enriching primate naive pluripotent stem cells based on LTR7/HERVH-associated transcription, wherein LTR7/HERVH-associated transcription is a marker for primate naive pluripotent stem cells. An isolated in vitro population of primate naive pluripotent stem cells is obtained by the method, wherein in the cells LTR7/HERVH-associated transcription is elevated in comparison to control cells, wherein control cells are primed pluripotent stem cells or differentiated cells.

公开(公告)号：US20220202854A1

公开(公告)日：2022-06-30

申请号：US17693500

申请日：2022-03-14

申请人： University of Louisville Research Foundation, Inc.

发明人： Suzanne T. Ildstad ,  Mary Jane Elliott

IPC分类号： A61K35/12 ,  A61K35/17 ,  A61K35/28 ,  C12N5/078 ,  C12N5/077 ,  C12N5/0789

摘要： The present disclosure relates to human facilitating cells (hFC), and methods of isolating, characterizing, and using such hFCs.

公开(公告)号：US11357800B2

公开(公告)日：2022-06-14

申请号：US16322248

申请日：2017-08-16

申请人： Henry Ford Health System

发明人： Zhenggang Zhang ,  Yi Zhang ,  Michael Chopp

IPC分类号： C12N5/02 ,  C12N5/071 ,  A61K35/44 ,  C07K14/00 ,  A61K35/30 ,  A61P25/02 ,  A61K31/282 ,  A61K31/4188 ,  A61K35/28 ,  A61K45/06 ,  A61K35/12

摘要： Without limitation, a method for preventing and/or treating neuropathic pain in a subject/patient comprising administering a therapeutically effective amount of exosomes derived and isolated from mammalian cells to the subject/patient and a method of treating cancer in a subject/patient in need thereof, comprises administering a combination comprising a therapeutically effective amount of exosomes derived and isolated from mammalian cells and a chemotherapeutic agent.

公开(公告)号：US11351200B2

公开(公告)日：2022-06-07

申请号：US16305011

申请日：2017-06-02

申请人： Cedars-Sinai Medical Center

发明人： Eduardo Marban ,  Eugenio Cingolani ,  James Dawkins

IPC分类号： A61K35/34 ,  C12N5/00 ,  A61K35/12 ,  A61P9/10 ,  A61P9/06 ,  A61K9/00 ,  A61N1/39

摘要： Described herein are compositions and methods related to use of exosomes, including cardiosphere derived cell (CDC)-derived exosomes for treatment and prevention of heart related disease and conditions, such as ventral arrhythmias, such as tachycardias. CDC-derived exosomes delivered by endocardial injection can diminish the total amount of isolated late potentials associated with an isthmus of slow conduction, while reducing the isoelectric interval between late abnormal ventricular activity and decreasing the incidence of inducible ventricular arrhythmias, thereby providing a biological treatment for arrhythmias which otherwise requires therapeutic interventions with adverse effects.

公开(公告)号：US20220168215A1

公开(公告)日：2022-06-02

申请号：US17672576

申请日：2022-02-15

申请人： TAIWAN MITOCHONDRION APPLIED TECHNOLOGY CO., LTD.

发明人： Hong-Lin SU ,  Hsueh-Min TSENG ,  Shih-Fang WU

IPC分类号： A61K8/98 ,  A61K35/12 ,  A61K9/00 ,  A61K9/08 ,  A61K47/02 ,  A61K35/407 ,  A61Q19/08

摘要： A composition with exogenous mitochondria as active ingredients, and a use thereof and a cell repairing method therefor. The composition includes exogenous mitochondria and at least one pharmaceutically or cosmetically acceptable carrier. The composition may further include an adjuvant, and the adjuvant is selected from a group consisting of serum, plasma, complement and at least the above two ingredients. The exogenous mitochondria are obtained from cells by a centrifugal purification method.

公开(公告)号：US20220167599A1

公开(公告)日：2022-06-02

申请号：US17675693

申请日：2022-02-18

申请人： The Trustees of Columbia University in the City of New York

发明人： Megan Sykes

IPC分类号： A01K67/027 ,  A61K35/28 ,  A61K35/12 ,  C12N5/0789 ,  C12N5/077

摘要： The invention provides for transgenic donor animals (e.g., pigs) whose cells, tissues and organs have a better long-term survival when transplanted into a human patient. The transgenic donor animal carries one or more human transgenes which is expressed only when the endogenous gene of the donor animal is knocked out shortly before a graft is harvested for transplantation. This “genetic switch” allows the donor animal to remain healthy during the majority of its lifetime, while still allowing expression of the human transgene for optimal transplant tolerance in a human recipient. The transgene may encode a cytokine receptor, an adhesion molecule, or a complement regulatory protein.

公开(公告)号：US11339410B2

公开(公告)日：2022-05-24

申请号：US16654726

申请日：2019-10-16

申请人： Factor Bioscience Inc.

发明人： Matthew Angel ,  Christopher Rohde

IPC分类号： C07H21/04 ,  C12N15/63 ,  C12N15/90 ,  A61K31/7115 ,  C12N9/22 ,  C07K14/195 ,  C12N15/10 ,  A61K35/14 ,  A61K38/46 ,  A61K48/00 ,  C12N15/86 ,  G01N33/50 ,  A61K31/70 ,  A61K35/12

摘要： The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.

公开(公告)号：US11332504B2

公开(公告)日：2022-05-17

申请号：US16739561

申请日：2020-01-10

申请人： Brandeis University

发明人： Greg Petsko ,  Dagmar Ringe ,  Shulin Ju

IPC分类号： A61K38/00 ,  A61K49/00 ,  C07K14/00 ,  C07K14/48 ,  C12N15/00 ,  C12N15/09 ,  C12N15/12 ,  C12N15/13 ,  C12N15/11 ,  C07K14/47 ,  A61K38/17 ,  G01N33/50 ,  A61K9/00 ,  C12Q1/02 ,  A61K31/7125 ,  A61K48/00 ,  A61K31/7088 ,  A61K31/711 ,  A61K31/7105 ,  A61K31/7115 ,  C12Q1/6883 ,  A61K35/12 ,  C12N15/85 ,  A61P3/00 ,  A01K67/027

摘要： Nonsense-mediated mRNA decay (NMD) polypeptides, nucleic acids encoding NMD polypeptides, and methods of using such polypeptides and nucleic acids in the treatment of ALS and in screening for agents for the treatment of ALS are described.